A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
← catalyst calendarNCT05355701 · readout in 613 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
267estimated
Sites
40
Countries
Canada, Israel, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-05 | actual | When the study began enrolling |
| Primary completion | 2028-04-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-25 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma
- Non-Small-Cell Lung Cancer
- Thyroid Cancer
- Glioma
- Advanced Colorectal Cancer (Part 1)
Interventions
- Drug: PF-07799933 — also filed as ARRY-440
- Drug: binimetinib — also filed as Mektovi, PF-06811462, MEK162
- Biological: cetuximab — also filed as Erbitux
- Drug: midazolam
- Drug: fluorouracil
- Drug: leucovorin
- Drug: oxaliplatin
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2)
measured Cycle 1 (21 days)
Number of participants with treatment-emergent adverse events (AEs) (Part 1 and Part 2)
measured Baseline to 28 days after last dose of study medication
Number of participants with clinically significant change from baseline in laboratory abnormalities (Part 1 and Part 2)
measured Baseline to 28 days after last dose of study treatment
Number of participants with clinically significant change from baseline in vital sign abnormalities (Part 1 and Part 2)
measured Baseline to 28 days after last dose of study treatment
Dose interruptions due to AEs (Part 1 and Part 2)
measured Baseline to 2 years
Dose dose modifications due to AEs (Part 1 and Part 2)
measured Baseline to 2 years
Discontinuations due to AEs (Part 1 and Part 2)
measured Baseline to 2 years
Overall response rate (ORR) (Part 3)
measured Baseline to 2 years
Number of participants with clinically significant physical exam abnormalities (Part 1 and Part 2)
measured Baseline to 28 days after last dose of study treatment
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed